News | August 28, 2021
Covid-19 infected individuals need only one dose of Covaxin: ICMR study
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Filing for WHO Emergency Use Authorisation this month
Subscribe To Our Newsletter & Stay Updated
